For the Inventor, By the Inventor

Enter assignee name

Madison, NJ, United States of America

Wyeth

USPTO Granted Patents = 1,309

CIPO Patents = 730

EPO Patents = 254

Trademarks = 184

Forward Citations = 12,827

Loading Chart...

Loading Chart...

2,146 inventors (with patents filed for the assignee):

Gary Paul Stack (61 out of 92 patents)

Syed Muzafar Shah (41 out of 93 patents)

Derek Cecil Cole (34 out of 42 patents)

4. Eugene John Trybulski (32 out of 32 patents)

5. Michael G Kelly (31 out of 72 patents)

6. Hassan Mahmoud Elokdah (31 out of 47 patents)

7. Andrew Fensome (30 out of 56 patents)

8. Mark Edward Ruppen (29 out of 59 patents)

9. Michael Sotirios Malamas (29 out of 76 patents)

10. Jay Edward Wrobel (26 out of 96 patents)

11. Puwen Zhang (26 out of 51 patents)

12. Ronald Charles Bernotas (26 out of 28 patents)

13. Amedeo A Failli (26 out of 79 patents)

14. Tianmin Zhu (25 out of 30 patents)

15. Annaliesa Sybil Anderson (24 out of 55 patents)

Core Competencies:

Pneumococcal Polysaccharide-Protein Conjugates

Sustained Release Pharmaceutical Compositions

Designer Osteogenic Proteins

Antineoplastic Combinations

Clostridium Difficile Toxin

Protein Production

Imatinib Resistant Leukemia

Gefitinib Resistant Cancer

Oral Formulations

High-Cell Density Fermentation

Sympathomimetic Amine Salts

Lyophilization Techniques

1,309 patents: Sort by Forward Citations

1. 12303592 - Formulations for parenteral delivery of compounds and uses thereof (2025-05-20),

2. 12226470 - Pneumococcal dosing regimen (2025-02-18),

3. 12054762 - Methods of protein production using anti-senescence compounds (2024-08-06),

4. 11969474 - Multivalent pneumococcal polysaccharide-protein conjugate composition (2024-04-30),

5. 11535652 - Compositions relating to a mutant clostridium difficile toxin and methods thereof (2022-12-27),

6. 11376315 - Method for controllingpolysaccharide molecular weight using carbon dioxide (2022-07-05),

7. RE48863 - Compositions relating to a mutanttoxin and methods thereof (2021-12-27),

8. RE48862 - Compositions relating to a mutanttoxin and methods thereof (2021-12-27),

9. 11191830 - Process for preparing pneumococcal polysaccharide-protein conjugates (2021-12-07),

10. 11179369 - Sustained release pharmaceutical compositions (2021-11-23),

11. 11167020 - Pneumococcal dosing regimen (2021-11-09),

12. 11103497 - Treatment of imatinib resistant leukemia (2021-08-31),

13. 11077180 - Non-lipidated variants ofORF2086 antigens (2021-08-03),

14. 11008373 - Designer osteogenic proteins (2021-05-18),

15. 10780160 - Process for preparing pneumococcal polysaccharide-protein conjugates (2020-09-22),

Wyeth is a global pharmaceutical company that focuses on discovering, developing, manufacturing, and marketing prescription drugs. With a mission to improve lives, Wyeth invests heavily in research and development to bring innovative therapies to patients in need. By collaborating with healthcare professionals and leveraging advanced technologies, Wyeth contributes to advancing medical science and improving the quality of healthcare worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

1,309 Patents

#3 in Madison, NJ

#27 in New Jersey

#377 in US

#739 in the World

Madison, NJ, United States of America

Wyeth

Forward Citations = 12,827

2,146 inventors:

Gary Paul Stack (61 out of 92 patents)

Syed Muzafar Shah (41 out of 93 patents)

Derek Cecil Cole (34 out of 42 patents)

4. Eugene John Trybulski (32 out of 32 patents)

5. Michael G Kelly (31 out of 72 patents)

Please report any incorrect information to support@idiyas.com

Loading…